MOPIPP 是一种新型吲哚基查尔酮、液泡素-1,是一种 MOMIPP (HY-148114) 的非致命液泡诱导 2-丙基类似物。MOPIPP 能诱导细胞液泡化,增加自噬体数目。MOPIPP 还会引发细胞巨泡式死亡 (methuosis),并中断葡萄糖摄取和糖酵解代谢。MOPIPP 能够透过血脑屏障,对胶质母细胞瘤细胞有抑制作用。
生物活性 | MOPIPP is a novel indolebased chalcone, and vacuolin-1, is a non-lethal vacuoleinducing 2-propyl analog ofMOMIPP(HY-148114). MOPIPP induces cellular vacuolization and increases autophagosomes numbers. MOPIPP also triggersmethuosis, and interrupts glucose uptake and glycolytic metabolism. MOPIPP can cross the blood-brain barrier and shows efficacy in suppressing tumor progression agaisnt glioblastoma cells[1][2][3]. |
体外研究 (In Vitro) | MOPIPP (10 μM; 48 h) induces cellular vacuolization but does not cause cell death in U251 glioblastoma cells, exhibiting characteristics of late endosomes[1][2]. MOPIPP (10 μM; 24 h) results an increasing LC3 fluorescence associated with the number of autophagosomes and inhibits fusion of autophagosomes with lysosomes[1]. MOPIPP (10 μM; 24 h) increases the amounts of exosomal marker proteins in vesicle fractions recovered from 293T cells[2]. MOMIPP (10 μM; 24 h and 5 h, respectively) causes early disruptions of glucose uptake and glycolytic metabolism, induces methuosis, a form of non-apoptotic cell death, in glioblastoma and other cancer cell lines[3]. MOMIPP (10 μM; 4 h and 24 h) selectively activates the JNK1/2 stress kinase pathway, resulting in phosphorylation of c-Jun, Bcl-2 and Bcl-xL[3].
Immunofluorescence[1] Cell Line: | U251 glioblastoma cells | Concentration: | 10 μM | Incubation Time: | 24 hours; incubated with 2.5 μg/mlAcridine Orange(HY-101879) for 45 min | Result: | Caused accumulation of autophagosome markers. Increased punctate LC3 fluorescence and suggested an increase in the number of autophagosomes in cells. |
Western Blot Analysis[3] Cell Line: | U251 glioblastoma cells | Concentration: | 10 μM | Incubation Time: | 4 and 24 hours | Result: | Triggered increaseing phosphorylation of Bcl-2 and Bcl-xL, accompanied the activation of JNK. |
|
体内研究 (In Vivo) | MOMIPP (80 mg/kg; i.p.; single dose) readily penetrates the bloodbrain barrier in female Swiss Webster Mice and (80 mg/kg; i.p.; every 24 h; 15 d) is effective in suppressing progression of intracerebral glioblastoma xenografts in female NCR-Foxn1mice[3].
Animal Model: | Intracerebral xenograft model in NCR-Foxn1mice (female, 7-8 weeks, injected with U251- LUC cells)[3] | Dosage: | 80 mg/kg | Administration: | Intraperitoneal injection; every 24 hours for 15 days; monitored tumor progression by BLI on the days 7, 11, 15 | Result: | Significantly inhibited tumor progression. |
|
分子量 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |